Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
Huihan Wang,Hua Shi,Xiaowei He,Aijun Liao
DOI: https://doi.org/10.2147/OTT.S300328
IF: 4
2021-04-22
OncoTargets and Therapy
Abstract:Huihan Wang, Hua Shi, Xiaowei He, Aijun Liao Haematology Department of Shengjing Hospital, China Medical University, Shenyang, People's Republic of China Correspondence: Aijun Liao Haematology Department of Shengjing Hospital, China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, People's Republic of China Tel +86-18940259833 Email Objective: Few studies have focused on investigating resistance mechanisms in myeloma immunotherapy. This study aimed to explore the relevant factor involved in the resistance of Elotuzumab and lenalidomide. Methods: Cell models which are resistant to Elotuzumab and lenalidomide were constructed; different expression genes in U266/WT (UW) and resistant UR, UE, and URE cells were detected by using gene expression microarray. RT-qPCR validated CCL20 mRNA expression of four cell lines and patient samples; bioinformatics analysis of CCL20 expressions in NDMM and RRMM; ELISA detected the presence of CCL20 in the plasma of MM patients; constructed UR mouse xenograft model to explore whether or not CCL20 reverse lenalidomide treatment in vivo. Results: Cell models which are resistant to Elotuzumab and lenalidomide (UR, UE, URE) were successfully constructed. CCL20 gene expression decreased in resistant myeloma cell lines and RRMM patients. Furthermore, RRMM patients were found to have lower levels of CCL20 protein in their plasma compared to NDMM. CCL20 increase the sensitivity of drug-resistant myeloma cells to immunomodulatory drugs both in vivo and in vitro. Conclusion: The expression of CCL20 was decreased in lenalidomide and Elotuzumab resistant U266 cells and in RRMM patients. CCL20 could therefore possibly increase the sensitivity of lenalidomide and Elotuzumab. Keywords: CCL20, elotuzumab, lenalidomide, drug resistance, multiple myeloma Multiple myeloma (MM) is a second hematologic malignancy commonly associated with the elderly population. Although the development of new drugs and treatment procedures have resulted in significant improvements in the response and survival rates of MM patients, it is still incurable, 1 with many patients still progressing to relapse/refractory MM (RRMM). Immunotherapy has attracted increasing attention in the treatment of multiple myeloma due to its advantages of targeting ability and low toxicity level. 2 While there are few studies on the mechanism of immunotherapy resistance, the ability of lenalidomide to regulate the immune function as a second generation of immunomodulators has widely been adopted in the treatment of MM. Elotuzumab (Elo) is the second monoclonal antibody drug approved for the treatment of RRMM in combination with lenalidomide and dexamethasone (E-Rd regimen). 3 , 4 The therapeutic target of Elotuzumab is a member of the signal lymphocyte activating molecule family 7 (slamf7, also known as CD319, CS1). CS1 is a cell surface glycoprotein molecule, with a very high expression on the surface of myeloma cells and differentiation stages of normal B cells. 5 Elotuzumab can directly activate NK cells and induce CD16 mediated cytotoxicity to kill myeloma cells with high expressions of CS1. While the E-Rd regimen achieved satisfactory results, there was an emergence of resistance to the drug in some patients. The resistance mechanism of immunotherapy is quite different from that of small molecule chemical drugs. The effectiveness of immunotherapy depends on the normal function of immune cells, especially T cell function, including recognition, chemotaxis, and the regulation of killing by cytokines. In this study, we developed resistant cell lines with resistance to Elotuzumab and lenalidomide, and we explored the mechanism involved in the resistance to monoclonal antibody and immunotherapy with the primary aim of providing new targets for immunotherapy and uncovering new procedures to reverse drug resistance. Bone marrow samples of MM patients were sorted using CD138 magnetic beads obtained from Shengjing Hospital of China Medical University. The Medical Ethics Committee at the Shengjing Hospital of China Medical University approved the present study based on the principles of the Declaration of Helsinki. Informed consent was granted by all participating patients in the study, as shown by their endorsement of the consent form. Myeloma drug-naive U266 cell line (U266/WT, UW) and lenalidomide-resistant cell line (U266/R10R, UR) were provided by Professor Orlowski Robert from the MD Anderson Cancer Centre. UW and UR cell lines were initially exposed to Elotuzumab at 10% minimum inhibitory concentration (IC10), and co-cultured with human peripheral bl -Abstract Truncated-
oncology,biotechnology & applied microbiology